PDCD1 and cancer: Increasing evidence showed risk factors such as loss of neoantigens, cancer-derived exosomes, high tumor mutation burden, immune inhibitory molecules, and T cells exclusion might contribute to the drug resistance of anti-PD-1 therapy [12,13].